CSI-Sydney: New Technologies To Treat Chronic Sinus Infection
Funder
National Health and Medical Research Council
Funding Amount
$412,213.00
Summary
Chronic sinus infection (CSI) is prevalent and results in severe discomfort and pain for many Australians; yet amazingly, has no specific cure or effective treatment. Our multi-disciplinary research team and an Australian health and medical research company, (AFT Pharmaceuticals) have partnered to develop a novel device that specifically targets the sinuses and a formulation capable for simultaneously removing mucus, dispersing biofilms and killing bacteria in the nasal cavities.
Peptide Therapeutics For The Treatment Of Autoimmune Diseases: Stability, Delivery And Disposition
Funder
National Health and Medical Research Council
Funding Amount
$368,467.00
Summary
Autoimmune diseases affect around 120 million people worldwide. This project will progress the development of a peptide that suppresses disease-causing autoantigen-specific immune responses without affecting protective responses. Different routes of delivery for this peptide will be evaluated, as well as slow-release formulations that will extend its in vivo lifetime. The outcome will be a patient-friendly form of this therapeutic lead that can be taken forward to preclinical evaluation.
Targeting Cystic Fibrosis Using A Novel Inhalation Therapy
Funder
National Health and Medical Research Council
Funding Amount
$421,545.00
Summary
Currently treatments for cystic fibrosis infection are via oral, intravenous or lengthy inhalation processes. This can lead to significant side effects, consequent poor patient compliance, and limited therapeutic efficacy. We will develop and test a novel high-dose inhalation dry power device containing an antibiotics for the rapid treatment of infection in cystic fibrosis therapy.